Justin Petrone

The Glaswegian company plans to commence a clinical feasibility study of its point-of-care diagnostic platform next year.

New regulations, politics, and the economy have transformed the UK's in vitro diagnostic industry the past few years, and more adjustments are on the horizon.

The firm recently received a European Innovation Council grant worth €5.7 million, and is planning further clinical validation of its platform while it eyes a US entry as soon as next year.

Mobvec will see the development of a new kind of mobile laboratory to support public health responses to vector-borne diseases.

Sphere Fluidics is the sole commercial partner and has the right to commercialize any resulting technology.

After having cut its teeth on the cannabis, food, and COVID-19 testing markets, PathogenDx is now poised to launch a microarray-based test for urinary tract infections.

The five-year, EU-funded project, called MensEndoDiag, will explore the use of menstrual blood as a sample type.

The envisioned test will involve measuring protein biomarkers in samples obtained by liquid biopsy, as well as artificial intelligence-based analysis tools.

Ibex announced earlier this month that it had secured several contracts to offer Galen Prostate and Galen Breast to 25 UK National Health Service trusts.

DNADX will be launched as an RUO test while the firm continues to work toward setting up a US laboratory.